drugset / Trial / NCT02478333

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ALS-008176 in Healthy Japanese Adult Participants

NCT02478333

Phase 1 Completed 24 enrolled Janssen Pharmaceutical K.K.
RandomizedParallel-groupDouble-blind

Summary

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of ALS-008176 following oral administration of single ascending dose of ALS-008176 in healthy Japanese adult participants.

Timeline

Start
2015-05
Primary completion
2015-07
Completion
2015-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Lumicitabine Small molecule 250 mg Oral
Subject Lumicitabine Small molecule 500 mg Oral
Subject Lumicitabine Small molecule 750 mg Oral